TNFRSF6B and cancer: It is highly expressed in various cancer types, especially BC.23 This study confirmed that Pyrotinib combined with Trastuzumab has high application value in HER-2 positive BC, and can downregulate the expression of COX-2, DcR3 and Caspase-3, and improve the prognosis of the disease.